Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturer:
|
Neostigmine Methylsulphate Injection Neostigmine metilsulfate 2.5mg/mL Solution for injection Max Health Limited Hameln Pharmaceuticals GmbH, Hameln, Germany
|
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturers:
|
Pomalyst Pomalidomide 1mg Capsule Celgene Limited Celgene International Sarl, Boudry, Switzerland Penn Pharmaceutical Services Limited, Gwent, United Kingdom
|
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturers:
|
Pomalyst Pomalidomide 2mg Capsule Celgene Limited Celgene International Sarl, Boudry, Switzerland Penn Pharmaceutical Services Limited, Gwent, United Kingdom
|
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturers:
|
Pomalyst Pomalidomide 3mg Capsule Celgene Limited Celgene International Sarl, Boudry, Switzerland Penn Pharmaceutical Services Limited, Gwent, United Kingdom
|
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturers:
|
Pomalyst Pomalidomide 4mg Capsule Celgene Limited Celgene International Sarl, Boudry, Switzerland Penn Pharmaceutical Services Limited, Gwent, United Kingdom
|
Dated this 12th day of March 2015.
SARAH READER, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).